This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies
Histological confirmation of hematological malignancies Acute leukemias Acute Myeloid Leukemia (AML) and related precursor neoplasms Favorable risk AML is defined as having one of the following: Acute lymphoblastic leukemia (ALL)/lymphoma Myelodysplasia (MDS) IPSS INT-2 or High Risk (i.e. RAEB, RAEBt) or Refractory Anemia with severe pancytopenia, transfusion dependence, or high risk cytogenetics or molecular features. Age 60 years of age or younger at the time of consent Karnofsky performance status ≥ 70% or Lansky play score 50% for ≤16 years of age. Adequate organ function
Exclusion Criteria:
Pregnant or breastfeeding. Active uncontrolled infection within 1 week of starting preparative therapy Known seropositive for HIV or known active Hepatitis B or C infection with detectable viral load by PCR. Any prior autologous or allogeneic transplant CML blast crisis Active central nervous system malignancy
